BioSpace News Archive

Vivani Medical, Inc., an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, reported financial results for the third quarter of 2023 and provided a business update.

KalVista Pharmaceuticals, Inc. announced that it presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema attacks and patient perspectives on why people living with HAE don’t often carry their on-demand treatment outside the home at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology in Anaheim, CA.

Affimed N.V. reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.

Castellum, Inc. announces highlights of its operating results for its third quarter ended September 30, 2023.

Asensus Surgical, Inc. announced that a Senhance® Surgical System was sold to the Company’s distribution partner, and will be placed in a pediatric hospital in the Commonwealth of Independent States region.

NanoViricides, Inc. reports that its broad-spectrum antiviral drug candidate, NV-387 was highly effective in an animal model that is used in drug development for MPox and Smallpox virus infections in humans.

Alvotech and JAMP Pharma Group announced that Health Canada has granted JAMP Pharma marketing authorization for AVT04, a biosimilar to Stelara® developed by Alvotech.

Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, provided a business update and reported financial results for the quarter ended September 30, 2023.

Autifony Therapeutics Limited announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

BerGenBio ASA announced financial results for the quarter ended September 30, 2023, and provided a business update.